Clinical trials: Neuromuscular Disease
Painful Diabetic Neuropathy, Diabetic Neuropathy
Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy
The purpose of the study is to determine whether clonidine gel is an effective treatment for reducing the pain associated with painful diabetic neuropathy.
- Conditions
- Painful Diabetic Neuropathy, Diabetic Neuropathy, Neuropathy
- Trial name
- NCT02068027
- Testing
- Clonidine Gel 0.1%
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- BioDelivery Sciences International
Chronic Inflammatory Demyelinating Polyneuropathy
Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic demyelinating polyneuropathy of autoimmune origin with a progressive or relapsing course.
- Trial name
- HELIPAD 1 (NCT03779828)
- Testing
- HOME LINK
- Where
- 10 sites in France
- Volunteers
- 11 people
- Sponsor
- CSL Behring
Chronic Inflammatory Demyelinating Polyneuropathy
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP.
- Trial name
- INVGOR (NCT07027111)
- Testing
- NVG-2089
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nuvig Therapeutics, Inc.
Spasticity
Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe.
- Trial name
- NCT06150729
- Where
- 8 sites in Mexico
- Volunteers
- 107 people
- Sponsor
- AbbVie
Amyotrophic Lateral Sclerosis (ALS)
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
The primary objective of this study is to evaluate the efficacy of 60mg of MCI-186 via intravenous drip once a day in patients with ALS whose severity is classified as grade III, based on the changes in the revised ALS functional…
- Trial name
- NCT00415519
- Testing
- MCI-186
- Volunteers
- 25 people
- Sponsor
- Shionogi
Pediatrics, Muscle Spasticity
BOTOX® Treatment in Pediatric Upper Limb Spasticity
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with upper limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Trial name
- NCT01603602
- Testing
- botulinum toxin Type A
- Where
- 45 sites in United States, Canada and 7 more
- Volunteers
- 235 people
- Sponsor
- Allergan
Diabetic Neuropathy
Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy
The purpose of this study is to assess the efficacy and safety of TRO19622 administered PO daily for 6 weeks compared to placebo administered PO daily in patients with painful peripheral diabetic neuropathy.
- Trial name
- NCT00496457
- Testing
- Experimental
- Where
- 31 sites in Croatia, Germany and 3 more
- Volunteers
- 159 people
- Sponsor
- Hoffmann-La Roche
Neurofibroma
Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia
The purpose of this study is to evaluate the effectiveness, safety of selumetinib and patient's parameters of symptomatic inoperable PN NF1 in real clinical practice in Russia
- Trial name
- NCT05891847
- Where
- 5 sites in Russia
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Diabetic Neuropathies
Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
To determine if duloxetine 60 mg once daily can work up to 6 months in treating pain from Diabetic Neuropathy.
- Trial name
- NCT00322621
- Testing
- Duloxetine
- Where
- 19 sites in Brazil, France and 2 more
- Volunteers
- 216 people
- Sponsor
- Eli Lilly and Company
Duchenne Muscular Dystrophy
Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy
This is a Phase 2 open-label extension (OLE) study to evaluate the long-term safety, tolerability, efficacy, pharmacokinetics, and the pharmacodynamics (PD) through potential exploratory biomarker(s) of intravenous (IV) WVE-N531…
- Trial name
- NCT07209332
- Testing
- WVE-N531
- Where
- 3 sites in Jordan, United Kingdom
- Volunteers
- 175 people
- Sponsor
- Wave Life Sciences USA, Inc.
Postherpetic Neuralgia
To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia
Investigate the Efficacy and Safety of HSK16149 capsules in Chinese Postherpetic Neuralgia Following 12 Weeks Treatment in Comparison to Placebo
- Trial name
- NCT05140863
- Testing
- HSK16149 20mg BID, HSK16149 40mg BID
- Where
- 2 sites in China
- Volunteers
- 372 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
ALS (Amyotrophic Lateral Sclerosis)
Ciprofloxacin/Celecoxib Combination in Patients With ALS
This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability, routine disease progression measures (ALSFRS-R and Vital…
- Trial name
- NCT04090684
- Testing
- Fixed dose combination Ciprofloxacin/Celecoxib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NeuroSense Therapeutics Ltd.
Diabetic Neuropathy
Study of DA-9801 to Treat Diabetic Neuropathy
To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.
- Trial name
- NCT01822925
- Testing
- DA-9801 300mg, DA-9801 600mg, DA-9801 900mg
- Where
- 14 sites in United States
- Volunteers
- 128 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
- Trial name
- NCT05869955
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 46 sites in United States, Belgium and 4 more
- Volunteers
- 270 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Optic Neuritis
Atacicept in Subjects With Optic Neuritis
This study was intended to evaluate the efficacy, safety and tolerability of atacicept compared to placebo and to explore the neuroprotective effect of atacicept as assessed by OCT in subjects with ON as CIS.
- Trial name
- NCT00624468
- Testing
- Atacicept
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 34 people
- Sponsor
- EMD Serono
Postherpetic Neuralgia
A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia
Pregabalin is an alpha-2 delta ligand approved for the treatment of neuropathic pain, however, not all patients will respond to this drug.
- Trial name
- NCT00599638
- Testing
- pregabalin, pregabalin/PF-00489791
- Where
- 39 sites in United States
- Volunteers
- 72 people
- Sponsor
- Pfizer
Neuralgia, Epilepsy
Clinical Study With Lyrica In Patients Suffering From Epilepsy
Clinical study with Lyrica (pregabalin) in patients suffering from epilepsy. This drug is used as adjunctive therapy with one or more antiepileptics. Lyrica has potential to reduce seizure frequency.
- Trial name
- NCT00922987
- Testing
- Lyrica (pregabalin)
- Where
- 61 sites in Slovakia
- Volunteers
- 286 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants
This is a Phase 1, single-center study conducted in 2 parts: Part 1a, single ascending dose (SAD-TDU16519): Double-blind, randomized, placebo-controlled sequential ascending single oral doses including up to 6 cohorts.
- Trial name
- NCT05795907
- Testing
- SAR443820
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Sanofi
Spinal Muscular Atrophy
A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular Disorders
The primary objective of the study is to explore the convergent validity of smartphone-based Konectom DOAs against in-clinic standard assessments.
- Trial name
- DigiNOA (NCT05109637)
- Testing
- Konectom NMD Application
- Where
- 5 sites in Germany
- Volunteers
- 93 people
- Sponsor
- Biogen
Hyperhidrosis, Muscle Spasticity
Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea
This post marketing surveillance study in Korea will evaluate the safety and efficacy of BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of care for primary axillary hyperhidrosis, focal…
- Conditions
- Hyperhidrosis, Muscle Spasticity, Glabellar Lines
- Trial name
- NCT02043145
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 727 people
- Sponsor
- Allergan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.